-
EP3543341
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3543341
| EP3543341 - ANTISENSE NUCLEIC ACIDS [Right-click to bookmark this link] | Status | The application has been withdrawn Status updated on 19.04.2024 Database last updated on 30.10.2024 | |
| Former | Examination is in progress Status updated on 14.08.2019 | Most recent event Tooltip | 19.04.2024 | Withdrawal of application | published on 22.05.2024 [2024/21] | Applicant(s) | For all designated states Nippon Shinyaku Co., Ltd. 14, Kisshoin Nishinosho Monguchicho Minami-ku Kyoto-shi Kyoto 601-8550 / JP | For all designated states National Center of Neurology and Psychiatry 1-1, Ogawa-Higashi-cho, 4-chome Kodaira-shi Tokyo 187-8551 / JP | [2019/39] | Inventor(s) | 01 /
WATANABE, Naoki Room 402, Ruvio II 21-3 Sakura 1-chome Tsukuba-shi Ibaraki, 305-0003 / JP | 02 /
SATOU, Youhei Room 401, Ruvio II 21-3 Sakura 1-chome Tsukuba-shi Ibaraki, 305-0003 / JP | 03 /
TAKEDA, Shin'ichi c/o National Center of Neurology and Psychiatry 1-1 Ogawahigashicho 4-chome Kodaira-shi Tokyo, 187-8551 / JP | 04 /
NAGATA, Tetsuya c/o National Center of Neurology and Psychiatry 1-1 Ogawahigashicho 4-chome Kodaira-shi Tokyo, 187-8551 / JP | [2019/39] | Representative(s) | Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE | [N/P] |
| Former [2019/39] | HGF Limited 4th Floor Merchant Exchange 17-19 Whitworth Street West Manchester M1 5WG / GB | Application number, filing date | 19169673.1 | 31.08.2011 | [2019/39] | Priority number, date | JP20100196032 | 01.09.2010 Original published format: JP 2010196032 | [2019/39] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3543341 | Date: | 25.09.2019 | Language: | EN | [2019/39] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 26.07.2019 | Classification | IPC: | C12N15/113, C12N15/11 | [2019/39] | CPC: |
A61P21/00 (EP);
C12N15/113 (EP,KR,US);
C07H21/04 (KR,US);
A61K31/7125 (KR);
C07H21/00 (US);
C07K14/4708 (EP);
C12N15/111 (EP,US);
C12N2310/11 (EP,US);
C12N2310/3145 (US);
C12N2310/315 (EP,US);
C12N2310/321 (EP,US);
C12N2310/3525 (EP,US);
C12N2320/33 (EP,US)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2019/39] | Title | German: | ANTISENSE-NUKLEINSÄUREN | [2019/39] | English: | ANTISENSE NUCLEIC ACIDS | [2019/39] | French: | ACIDES NUCLÉIQUES ANTISENS | [2019/39] | Examination procedure | 16.04.2019 | Examination requested [2019/39] | 26.07.2019 | Date on which the examining division has become responsible | 20.08.2019 | Despatch of a communication from the examining division (Time limit: M06) | 25.02.2020 | Reply to a communication from the examining division | 08.07.2020 | Despatch of a communication from the examining division (Time limit: M04) | 23.10.2020 | Reply to a communication from the examining division | 26.02.2021 | Observations by third parties | 27.05.2021 | Despatch of a communication from the examining division (Time limit: M06) | 04.03.2022 | Reply to a communication from the examining division | 17.06.2022 | Despatch of a communication from the examining division (Time limit: M06) | 24.01.2023 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time | 21.03.2023 | Reply to a communication from the examining division | 07.11.2023 | Cancellation of oral proceeding that was planned for 18.12.2023 | 18.12.2023 | Date of oral proceedings (cancelled) | 15.04.2024 | Application withdrawn by applicant [2024/21] | 15.04.2024 | Cancellation of oral proceeding that was planned for 18.04.2024 | 18.04.2024 | Date of oral proceedings (cancelled) | Parent application(s) Tooltip | EP11821996.3 / EP2612917 | EP15199455.5 / EP3018211 | Divisional application(s) | EP24168460.4 | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the examination report | 21.03.2023 | Request for further processing filed | 21.03.2023 | Full payment received (date of receipt of payment) Request granted | 28.03.2023 | Decision despatched | The application is deemed to be withdrawn due to failure to reply to the examination report | 04.03.2022 | Request for further processing filed | 04.03.2022 | Full payment received (date of receipt of payment) Request granted | 15.03.2022 | Decision despatched | Fees paid | Renewal fee | 16.04.2019 | Renewal fee patent year 03 | 16.04.2019 | Renewal fee patent year 04 | 16.04.2019 | Renewal fee patent year 05 | 16.04.2019 | Renewal fee patent year 06 | 16.04.2019 | Renewal fee patent year 07 | 16.04.2019 | Renewal fee patent year 08 | 01.08.2019 | Renewal fee patent year 09 | 20.08.2020 | Renewal fee patent year 10 | 10.08.2021 | Renewal fee patent year 11 | 17.08.2022 | Renewal fee patent year 12 | 16.08.2023 | Renewal fee patent year 13 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [AD]WO2010048586 (AVI BIOPHARMA INC [US], et al); | [ID]US2010168212 (POPPLEWELL LINDA [GB], et al); | by applicant | WO9109033 | JP2924179B | WO2004048570 | WO2006000057 | WO2009064471 | WO2010048586 | US2010168212 | JP2010196032 | WO2006JP38608 | WO2008JP96690 |